These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 10399633)

  • 1. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment.
    Swan SK; Lambrecht LJ; Townsend R; Davies BE; McCloud S; Parker JR; Bensel K; LaFrance ND
    Invest Radiol; 1999 Jul; 34(7):443-8. PubMed ID: 10399633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function.
    Davies BE; Kirchin MA; Bensel K; Lorusso V; Davies A; Parker JR; Lafrance ND
    Invest Radiol; 2002 May; 37(5):299-308. PubMed ID: 11979156
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and tissue distribution in animals of gadobenate ion, the magnetic resonance imaging contrast enhancing component of gadobenate dimeglumine 0.5 M solution for injection (MultiHance).
    Lorusso V; Arbughi T; Tirone P; de Haën C
    J Comput Assist Tomogr; 1999 Nov; 23 Suppl 1():S181-94. PubMed ID: 10608414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gadolinium Retention, Brain T1 Hyperintensity, and Endogenous Metals: A Comparative Study of Macrocyclic Versus Linear Gadolinium Chelates in Renally Sensitized Rats.
    Rasschaert M; Emerit A; Fretellier N; Factor C; Robert P; Idée JM; Corot C
    Invest Radiol; 2018 Jun; 53(6):328-337. PubMed ID: 29329151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gadobenate dimeglumine-enhanced MRI of the breast: analysis of dose response and comparison with gadopentetate dimeglumine.
    Knopp MV; Bourne MW; Sardanelli F; Wasser MN; Bonomo L; Boetes C; Müller-Schimpfle M; Hall-Craggs MA; Hamm B; Orlacchio A; Bartolozzi C; Kessler M; Fischer U; Schneider G; Oudkerk M; Teh WL; Gehl HB; Salerio I; Pirovano G; La Noce A; Kirchin MA; Spinazzi A
    AJR Am J Roentgenol; 2003 Sep; 181(3):663-76. PubMed ID: 12933457
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety of intravenous gadolinium (Gd-BOPTA) infusion in patients with renal insufficiency.
    Townsend RR; Cohen DL; Katholi R; Swan SK; Davies BE; Bensel K; Lambrecht L; Parker J
    Am J Kidney Dis; 2000 Dec; 36(6):1207-12. PubMed ID: 11096046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.
    Pirovano G; Kirchin MA; Lorusso V; Patel R; Shen N
    J Magn Reson Imaging; 2015 Apr; 41(4):1096-103. PubMed ID: 24807269
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gadolinium Retention in Erythrocytes and Leukocytes From Human and Murine Blood Upon Treatment With Gadolinium-Based Contrast Agents for Magnetic Resonance Imaging.
    Di Gregorio E; Furlan C; Atlante S; Stefania R; Gianolio E; Aime S
    Invest Radiol; 2020 Jan; 55(1):30-37. PubMed ID: 31503081
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Evaluation of Gadolinium Retention in Rat Brain After Single Injection of a Clinically Relevant Dose of Gadolinium-Based Contrast Agents.
    Strzeminska I; Factor C; Robert P; Grindel AL; Comby PO; Szpunar J; Corot C; Lobinski R
    Invest Radiol; 2020 Mar; 55(3):138-143. PubMed ID: 31917763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function.
    Swan SK; Baker JF; Free R; Tucker RM; Barron B; Barr R; Seltzer S; Gazelle GS; Maravilla KR; Barr W; Stevens GR; Lambrecht LJ; Pierro JA
    J Magn Reson Imaging; 1999 Feb; 9(2):317-21. PubMed ID: 10077031
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Quantitative Lung Perfusion Imaging Using the Dual-Bolus Approach: Comparison of 3 Contrast Agents and Recommendation of Feasible Doses.
    Veldhoen S; Oechsner M; Fischer A; Weng AM; Kunz AS; Bley TA; Köstler H; Ritter CO
    Invest Radiol; 2016 Mar; 51(3):186-93. PubMed ID: 26606550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study between gadobenate dimeglumine and gadobutrol in rats with brain ischemia: evaluation of somatosensory evoked potentials.
    Frigeni V; Miragoli L; Grotti And A; Lorusso V
    Invest Radiol; 2001 Oct; 36(10):561-72. PubMed ID: 11577266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double-blind, efficacy evaluation of gadobenate dimeglumine, a gadolinium chelate with enhanced relaxivity, in malignant lesions of the brain.
    Runge VM; Parker JR; Donovan M
    Invest Radiol; 2002 May; 37(5):269-80. PubMed ID: 11979153
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
    Bryant BJ; Im K; Broome DR
    Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Low-Dose Higher-Relaxivity and Standard-Dose Lower-Relaxivity Contrast Media for Delayed-Enhancement MRI: A Blinded Randomized Crossover Study.
    Cheong BY; Duran C; Preventza OA; Muthupillai R
    AJR Am J Roentgenol; 2015 Sep; 205(3):533-9. PubMed ID: 26295638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Focal liver lesions: whether a standard dose (0.05 mmol/kg) gadobenate dimeglumine can provide the same diagnostic data as the 0.1 mmol/kg dose.
    Nural MS; Gokce E; Danaci M; Bayrak IK; Diren HB
    Eur J Radiol; 2008 Apr; 66(1):65-74. PubMed ID: 17555901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low dose gadobenate dimeglumine for imaging of chronic myocardial infarction in comparison with standard dose gadopentetate dimeglumine.
    Bauner KU; Reiser MF; Huber AM
    Invest Radiol; 2009 Feb; 44(2):95-104. PubMed ID: 19077911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A clinical comparison of the safety and efficacy of MultiHance (gadobenate dimeglumine) and Omniscan (Gadodiamide) in magnetic resonance imaging in patients with central nervous system pathology.
    Runge VM; Armstrong MR; Barr RG; Berger BL; Czervionke LF; Gonzalez CF; Halford HH; Kanal E; Kuhn MJ; Levin JM; Low RN; Tanenbaum LN; Wang AM; Wong W; Yuh WT; Zoarski GH
    Invest Radiol; 2001 Feb; 36(2):65-71. PubMed ID: 11224753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
    Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
    Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics, dose proportionality, and tolerability of gadobutrol after single intravenous injection in healthy volunteers.
    Staks T; Schuhmann-Giampieri G; Frenzel T; Weinmann HJ; Lange L; Platzek J
    Invest Radiol; 1994 Jul; 29(7):709-15. PubMed ID: 7960618
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.